| Texto completo | |
| Autor(es): |
Serafim Junior, Vilson
[1]
;
de Mendonca Fernandes, Glaucia Maria
[1]
;
de Oliveira-Cucolo, Juliana Garcia
[1]
;
Pavarino, Erika Cristina
[1]
;
Goloni-Bertollo, Eny Maria
[1, 2]
Número total de Autores: 5
|
| Afiliação do(s) autor(es): | [1] UPGEM, Genet & Mol Biol Res Unit, Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, SP - Brazil
[2] Sao Jose Rio Preto Med Sch FAMERP, Dept Mol Biol, Genet & Mol Biol Res Unit UPGEM, Sect U6, Ave Brigadeiro Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | CYTOKINE; v. 136, DEC 2020. |
| Citações Web of Science: | 0 |
| Resumo | |
The tropomyosin-related kinase B (TrkB) receptor is a member of the neurotrophic tyrosine kinase receptors family and, together with the brain-derived neurotrophic factor (BDNF), plays an important role in the development of breast cancer, lung cancer, neuroblastoma, colorectal cancer, leukemia, cervical cancer, gallbladder cancer, gastric cancer, kidney cancer, Ewing's sarcoma, esophageal cancer, and head and neck cancer. Overexpression of these two factors has been associated with increased processes involved in carcinogenesis, such as invasion, migration, epithelial-mesenchymal transition (EMT), angiogenesis, metastasis, cell proliferation, resistance to apoptosis, resistance to cell death due to loss of adhesion (anoikis), activation of cell proliferation pathways, regulation of tumor suppressor genes, and drug resistance, and is related to advanced clinical stage. Inhibition of the TrkB/BDNF axis using drugs in phase 1 studies, approved drugs, and small interfering RNA (siRNA) are promising strategies for the treatment of various malignant tumors in addition to increasing the sensitivity of cells resistant to chemotherapy, improving the effectiveness of drugs without increasing toxicity. Another factor related to poor cancer prognosis is the presence of cancer stem cells, having effects similar to the high expression of the TrkB/BDNF axis, on cancer. This review aimed to show the role of the TrkB/BDNF axis in several types of cancer, its possible use as a prognostic biomarker, the effects of inhibiting this axis, and its role in the cancer stem cells. (AU) | |
| Processo FAPESP: | 18/26166-6 - Biomarcadores e células-tronco tumorais no tratamento do câncer de cabeça e pescoço |
| Beneficiário: | Eny Maria Goloni Bertollo |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |